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A B S T R A C T
Nanoparticles targeting transporters of the blood-brain barrier (BBB) are promising candidates to increase the
brain penetration of biopharmacons. Solute carriers (SLC) are expressed at high levels in brain endothelial cells
and show a speciﬁc pattern at the BBB. The aim of our study was to test glutathione and ligands of SLC
transporters as single or dual BBB targeting molecules for nanovesicles. High mRNA expression levels for hexose
and neutral amino acid transporting SLCs were found in isolated rat brain microvessels and our rat primary cell
based co-culture BBB model. Niosomes were derivatized with glutathione and SLC ligands glucopyranose and
alanine. Serum albumin complexed with Evans blue (67 kDa), which has a very low BBB penetration, was se-
lected as a cargo. The presence of targeting ligands on niosomes, especially dual labeling, increased the uptake of
the cargo molecule in cultured brain endothelial cells. This cellular uptake was temperature dependent and
could be decreased with a metabolic inhibitor and endocytosis blockers ﬁlipin and cytochalasin D. Making the
negative surface charge of brain endothelial cells more positive with a cationic lipid or digesting the glycocalyx
with neuraminidase elevated the uptake of the cargo after treatment with targeted nanocarriers. Treatment with
niosomes increased plasma membrane ﬂuidity, suggesting the fusion of nanovesicles with endothelial cell
membranes. Targeting ligands elevated the permeability of the cargo across the BBB in the culture model and in
mice, and dual-ligand decoration of niosomes was more eﬀective than single ligand labeling. Our data indicate
that dual labeling with ligands of multiple SLC transporters can potentially be exploited for BBB targeting of
nanoparticles.
1. Introduction
The blood-brain barrier (BBB) restricts the entry of the potential
neuropharmaceuticals, especially biopharmacons, like nucleic acids,
peptide or protein drugs into the central nervous system (CNS).
Although it is generally assumed that small molecule drugs can cross
the BBB, actually, only about a small fraction of them is able to enter
the brain parenchyma (Pardridge, 2015). Several clinical trials ended
with failure because of the low penetration of the biologic drugs across
the BBB (Pardridge, 2016). Strategies to solve this problem can be
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classiﬁed into three major groups, namely (i) circumvention of the BBB,
(ii) modiﬁcation of the BBB functions, (iii) modiﬁcation of the mole-
cules (Deli, 2011). Invasive drug delivery strategies, like in-
traventricular or intrathecal drug administration are successful in cir-
cumventing the BBB, however limitations, such as potential infectious
risks must be considered. The non-invasive alternative nasal pathway is
also being investigated for transport of molecules to the brain (Horvát
et al., 2009; Sipos et al., 2010) but the major drawbacks of this method
are the very low amount of molecules transported to the brain and
limited distribution. Modiﬁcation of BBB functions with transient in-
crease of brain endothelial permeability pathways (Hülper et al., 2013;
Walter et al., 2015) could potentially increase CNS drug delivery if
problems with safety, reversibility, systemic and CNS side-eﬀects will
be solved in the future. Medicinal chemistry uses several methods to
enhance brain delivery of molecules by changing their physico-che-
mical properties, including techniques to increase the lipid solubility or
cationic charge of molecules. While high lipid solubility can augment
the transport of a given drug across the BBB it can also enhance its
uptake by peripheral tissues and also sequestration in the capillary bed
resulting in decreased concentration in blood and in the CNS (Banks,
2009). Therefore new approaches are needed to improve the brain
delivery of drugs.
Nanosized drug carriers, or nanoparticles (NP) are in the focus of
research eﬀorts to develop successful drug delivery systems for the CNS
(Masserini, 2013; Saraiva et al., 2016; Zhou et al., 2018). Vesicular NPs
are especially versatile, because they can accomodate drug cargo with
diﬀerent properties. The non-ionic surfactant based vesicular nano-
carriers, niosomes, have several favorable properties such as good
biocompatibility and biodegradability, non-immunogenicity, and phy-
sical stability. Niosomes are also able to accumulate both water and
lipid soluble drugs and control their release (Abdelkader et al., 2014).
Another advantage of nanovesicles is that they increase the penetration
of drugs across biological barriers and reduce their toxic side eﬀects due
to the encapsulation process (Masserini, 2013). However, the en-
capsulation of drugs in NPs alone is not enough for the successful de-
livery of drugs to the CNS, speciﬁc targeting is needed to elevate the
BBB speciﬁc uptake and permeability of drugs (Kreuter, 2014). Various
essential inﬂux transport systems are expressed on the cerebral en-
dothelium, which have physiological role in the delivery of nutrients
and can be potentially exploited to shuttle nanocarriers to the brain,
including receptor mediated endocytosis, adsorptive mediated en-
docytosis and carrier mediated transport systems (Abbott, 2013;
Campos-Bedolla et al., 2014). The receptor mediated transport pathway
and the ligands of BBB receptors are widely investigated to deliver
fusion peptides or NPs to the brain (Pardridge, 2012; Johnsen and
Moos, 2016).
Solute carriers (SLC) compose a large family of transporters at the
BBB delivering nutrients (Enerson and Drewes, 2006; Campos-Bedolla
et al., 2014). Several clinically used drugs cross the endothelial cells of
brain capillaries via SLCs. The most well known drug to treat Parkin-
son's disease, L-DOPA, enters the brain via the LAT1/SLC7A5 trans-
porter (Pardridge, 2015). SLC transporters are actively investigated as
drug targets and the number of drug candidates developed for SLCs and
reaching clinical trials increases (Rask-Andersen et al., 2013). However
this pathway is not fully exploited for drug delivery (César-Razquin
et al., 2015), especially for targeted NPs.
Among the SLC transporters, the expression level of glucose trans-
porter GLUT1 (SLC2A1) is the highest at the BBB, but other members of
the SLC2A family are also present (Campos-Bedolla et al., 2014;
Enerson and Drewes, 2006). Glucose analogs have a potential to be
eﬃcient and selective targeting ligands for both vesicular and gold
nanocarriers to cross the BBB (Dufes et al., 2004; Gromnicova et al.,
2013). The number and expression level of SLCs transporting amino
acids across the BBB are also high (Enerson and Drewes, 2006;
Shawahna et al., 2011). Neutral amino acids, like alanine, serine and
cysteine, are transported by carriers belonging to the SLC38A sodium
coupled amino acid transporter family (SLC38A1, SLC38A2, SLC38A5)
and the SLC1A neutral amino acid transporters (ASCT1/SLC1A4,
ASCT2/SLC1A5) (Campos-Bedolla et al., 2014). These neutral amino
acids could be also considered as targeting molecules, but have not
been used for decorating nanocarriers yet. SLCs also transport vitamins
to brain (Campos-Bedolla et al., 2014). The Na+-dependent multi-
vitamin transporter SLC5A6 mediates the uptake of biotin in brain
endothelial cells (Uchida et al., 2015). We were the ﬁrst to demonstrate
that biotin as a targeting ligand signiﬁcantly elevated the uptake and
permeability of solid NPs in cultured human brain endothelial cells as
compared to non-targeted NPs (Veszelka et al., 2017). Since the ex-
pression pattern of SLCs is speciﬁc for the BBB, our hypothesis was that
labeling vesicular NPs with two diﬀerent SLC ligands (dual targeting)
will increase the brain endothelial uptake of the cargo and its perme-
ability across the BBB as compared to a single ligand.
One of the most successful targeting ligands of NPs to cross the BBB
is the tripeptide glutathione. There is an active glutathione transport
across the BBB, but the transporter(s) were not yet identiﬁed (Gaillard,
2016). Nevertheless glutathione, as a targeting ligand, increased drug
delivery to brain by NPs in several studies (Birngruber et al., 2014;
Lindqvist et al., 2016). The group of Gaillard established the eﬃcacy of
glutathione targeted liposomal doxorubicin in a mouse glioma model
(Gaillard et al., 2014) and these NPs were also investigated in clinical
trials (Gaillard, 2016).
The aim of our study was to test glucopyranose and alanine, ligands
of SLC transporters, as single or dual BBB targeting molecules for na-
novesicles loaded with a large biomolecule, serum albumin, as cargo.
Glutathione was used as a reference BBB targeting ligand. We char-
acterized the properties of the diﬀerent niosomes and investigated their
eﬀects on viability, cellular uptake and permeability of the cargo using
a BBB culture model. The mechanism of the cellular uptake process and
the role of the brain endothelial surface charge were also studied. Single
and dual-targeted niosomes were also examined in mice using optical
imaging.
2. Materials and methods
2.1. Animals
Animal studies were performed following the regulations of the
1998. XXVIII. Hungarian law and the EU Directive 2010/63/EU about
animal protection and welfare. Approval for animal studies was ob-
tained from the local animal health authority, the Governmental Oﬃce
for Csongrád County, Directorate of Food Chain Safety and Animal
Health (Permit numbers: XVI./03835/001/2006, XVI./834/2012). For
the in vivo experiments ten week old male CD1-Foxn1nu nude mice
(Charles River Laboratories, Wilmington, MA, USA) were used. For the
in vitro primary cell isolations, brain tissues were obtained from 3-week-
old and newborn outbred Wistar rats (Harlan Laboratories, United
Kingdom) of both sexes. Animals were fed on standard rodent chow and
water ad libitum and kept under a 12 h light/dark cycle in the con-
ventional animal house of the Biological Research Centre. During the
experiments, all eﬀorts were made to minimize animal suﬀering and
pain.
2.2. Materials
All reagents were purchased from Sigma-Aldrich Kft., Hungary (part
of Merck Life Science), except for those speciﬁcally mentioned.
2.3. Synthesis of targeted ligands for niosomes
For the synthesis of DSPE-PEG-glutathione, 13.5 mg glutathione
(0.044mM) was reacted with 100mg DSPE-PEG-maleimide
(0.035mM) (N-[(3-Maleimide-1-oxopropyl) aminopropyl poly-
ethyleneglycol-carbamyl] distearoylphosphatidyl-ethanolamine,
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SUNBRIGHT® DSPE-020MA (DSPE-PEG-MAL) obtained from NOF
Europe, Belgium) in 0.1M ammonium acetate for a day under nitrogen.
The product was lyophilized three times to remove ammonium acetate.
Dodecanoyl alanine was prepared according to the literature
method (Liu et al., 2014). Brieﬂy, 100ml NaOH (1M) and 1.34 g
(0.015mol) L-alanine were added into a one-neck ﬂask. After the
system was cooled to 0 °C, 3.31ml (0.014mol) dodecanoyl chloride was
added dropwise to the mixture and maintained for 5 h at 0 °C. Then
16ml hydrochloric acid (12M) was added to the reaction and the white
precipitate was ﬁltrated. Finally the product was washed three times
with deionized water and dried at 45 °C for 24 h.
2.4. Preparation of targeted niosomes loaded with albumin
Non-ionic surfactants, Span 60 (sorbitane-monostearate) and
Solulan C24 (cholesteryl-poly-24-oyxyethylene-ether, Chemron Co.
USA) were dissolved with cholesterol in hot 1:2 mixtures of chloroform
and ethanol in a round-bottom ﬂask. N-dodecyl-β-D-glucopyranose (GP,
9% (w/w) of total lipid), dodecanoyl-alanine (A, 5% (w/w) of total li-
pids) or pegylated-GSH (GSH, 5% (w/w) of total lipids) were added to
prepare targeted niosomes (N-GP, N-A, N-GSH) (Dufes et al., 2004;
Gaillard et al., 2014). For dual-targeted NPs (N-A-GP, N-A-GSH, N-GP-
GSH) the content of ligands was 4–4% (w/w) of the total lipids. The
removal of organic solvents by vacuum pump yielded a thin lipid ﬁlm
layer. The dry lipid ﬁlm was hydrated with phosphate buﬀer (PBS; KCl
2.7 mM, KH2PO4 1.5mM, NaCl 136mM, Na2HPO4× 2 H2O 6.5 mM,
pH 7.4) containing Evans blue-labeled bovine serum albumin (EBA,
67 kDa; 0.167mg/ml EB, 10mg/ml BSA). For transmission electron
microscopy niosomes with the electron dense lanthanum nitrate
(433 Da), as a cargo, were prepared. The mixture was heated at 40 °C in
a water bath and sonicated for 25min. The suspension was forced
through a polycarbonate ﬁlter (Whatman ﬁlter, 13mm, 100 nm pore
size) by lipid extrusion technique (high pressure thermobarrel extruder,
Lipex Biomembranes Inc. USA) to yield vesicles. The non entrapped
cargo was removed by ultracentrifugation (123,249 g, 6 h, 4 °C), the
pelleted niosomes were resuspended in PBS or DMEM medium and
stored at 4 °C.
2.5. Preparation of targeted niosomes loaded with lanthanum and
lanthanum measurement
For transmission electron microscopy experiments niosomes with
the electron dense lanthanum nitrate hexahydrate (433 Da), as a cargo
were prepared by hydrating the lipid ﬁlm with PBS containing 5mg/ml
lanthanum. The lanthanum content of the particles was determined by
a quadrupole Agilent 7700× inductively coupled plasma mass spec-
trometer (ICP-MS), was used for trace element analysis. The sample
introduction system consisted of an Agilent I-AS auto sampler and a
Micro Mist pneumatic nebulizer in a Peltier-cooled Scott-type spray
chamber. The sample uptake rate was 400 μL/min. The ICP plasma and
interface parameters were set up as follows: RF forward power: 1550W,
plasma gas ﬂow rate: 15.0 L/min, carrier gas ﬂow rate: 1.05 L/min,
sampling depth: 10.0 mm. Ultra trace quality HNO3 acid was also used
for the acid dissolution of the samples at 180 °C. The digestion time was
one hour. Signal tuning was performed by Agilent (No. G1820-60410)
solutions, whereas calibration was done using solutions prepared from
an Inorganic Ventures (Christiansburg, Virginia, USA) IV-ICPMS-71A
multielement stock standard. The 99.996% purity argon gas used was
purchased from Messer Hungarogáz (Hungary). Data processing was
performed within the Agilent Mass Hunter (Santa Clara, California,
USA) software.
2.6. Characterization of niosomes: Size, charge and encapsulation
eﬃciency
The NPs were characterized for particle size and zeta potential using
dynamic light scattering (Malvern Zetasizer Nano ZS, Worcestershire,
UK). Before measurements the niosome samples were diluted in PBS to
a ﬁnal concentration of 200 μg/mL. The means of particle size and zeta
potential data were calculated from the average of three measurements
per sample. To determine the amount of encapsulated dye in the NPs,
EBA was released from the niosomes with 50% v/v ethanol and mea-
sured by spectroﬂuorometer (Fluorolog 3, Horiba Jobin Yvon) at
584 nm excitation and 663 nm emission wavelengths. The concentra-
tions were determined from a standard ﬂuorescence calibration curve
(r2= 0.9985). The encapsulation eﬃciency % (EE%) was calculated by
the following equation:
= ×EE% Amount of EBA in the NP sample
Amount of EBA in the hydrating buffer
100
2.7. Characterization of niosomes: Transmission electron microscopy
Aliquots of the niosome samples (10 μL) were placed on formvar
carbon 400-mesh copper grids (Electron Microscopy Sciences,
Washington, PA, USA). Images were taken on a JEOL JEM-1400
transmission electron microscope (JEOL Ltd., Japan) operating at
120 kV. Images were captured routinely at magniﬁcations of 20,000×,
25,000× and 30,000×, and analyzed with a SightX Viewer Software
(EM-15300SXV Image Edit Software, JEOL Ltd., Tokyo, Japan).
2.8. Characterization of niosomes: Atomic force microscopy
A two-beam interference lithography arrangement was applied to
generate sub-micrometer periodic intensity modulation in the laser
beam irradiating the samples (Csete et al., 2007). The fourth harmonic
of a Nd:YAG laser (λFH=266 nm, t=10 ns, f= 10Hz) was diﬀracted
impinged on a reﬂective grating (PUV 1200, Spectrogon), and the ﬁrst
order diﬀracted beams were recombined at the sample surface. The
samples were NBK7 substrates evaporated by gold‑silver bimetallic
layers, and spin-coated by polycarbonate.
The samples were silicone wafer substrates spin-coated by poly-
carbonate, which were treated by s-polarized beams, to produce linear
gratings as described earlier (Csete et al., 2007). The laser treated
surfaces were scanned by atomic force microscopy (AFM) operating in
digital pulsed force mode (DPFM, Witec GmbH, Germany). The ad-
vantage of this scanning mode is the possibility to map the micro-
mechanical properties of the surface with high resolution. We applied
standard PFM tips (NSC 18/NoA1, 2.5 N/m) and collected pictures
about the topography and adhesion, which revealed that the adhesion is
stronger in the valleys of the linear grating, thus facilitating the de-
position of particles.
To examine niosomes the samples with laser-grated surfaces were
completely immersed in fresh PBS solutions containing niosomes.
Incubation of the samples in the solutions lasted for 1 h at 37 °C, then all
samples were washed three times in sterile distilled water on a hor-
izontal shaker and ﬁnally allowed to dry overnight at room tempera-
ture. An AFM (XE-100, PSIA Corp.) operating in tapping-mode was
applied to detect the attached biomolecules using tapping-mode NT-
MDT tips (NSG11, 5.5 N/m, 150 kHz, NT-MDT).
2.9. RNA isolation and quality control
Rat brain microvessels were isolated as described in our previous
article (Veszelka et al., 2007). Primary rat brain endothelial cells
(RBEC; isolated according to the method described in section 2.11. and
in our previous studies (Veszelka et al., 2007; Nakagawa et al., 2009;
Walter et al., 2015) were cultured for 5 days in 10 cm dishes. After
reaching conﬂuency the cells were scraped, collected and cell pellets
were used for total RNA isolation using RNAqueous-4PCR Kit (Ambion,
Life Technologies, Austin, TX, USA) with DNase1 (RNase-free) treat-
ment according to the manufacturer's instructions. The concentrations
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and purity of the DNase-treated RNA samples were assessed by a Na-
noDrop ND-1000 spectrophotometer (NanoDrop Technologies, Rock-
land, DE). The integrities of the isolated RNAs were characterized using
Bioanalyzer 2100 (Agilent Technologies, Santa Clara, CA). The RNA
integrity numbers (RIN) were between 9.2 and 10 in the case of all
studied RNA samples.
2.10. Quantitative real-time polimerase chain reaction and data analysis
In all cases, cDNA synthesis was performed on 1 μg total RNA
samples by High Capacity cDNA Reverse Transcription Kit (Life
Technologies) using random hexanucleotide primers and MultiScribe
Reverse Transcriptase in the presence of RNase inhibitor according to
the manufacturer's protocols. The expression of the genes of transpor-
ters for alanine (sodium-coupled neutral amino acid transporters,
Snat1/Slc38a1, Snat2/Slc38a2, Snat5/Slc38a5; neutral amino acid
transporters, Asct1/Slc1a4, Asct2/Slc1a5) and the genes of transporters
for glucose (Glut1/Slc2a1, Glut3/Slc2a3, Glut5/Slc2a5) were analyzed
by quantitative PCR using TaqMan Low Density Array 384-well mi-
croﬂuidic cards preloaded with TaqMan Gene Expression Assays (Life
Technologies). Quantitative real-time PCRs (qPCR) were performed by
ABI TaqMan Universal Master Mix (Life Technologies) using the ABI
Prism 7900 system (Applied Biosystems, Life Technologies). qPCR data
were analyzed using the ABI SDS 2.0 software (Applied Biosystems, Life
Technologies). In all samples the expression of genes was normalized to
18S rRNA, which was used as an endogenous control
(ΔCt=Ctgene− Ct18S rRNA). Expression values of studied genes were
determined based on the normalized expression of genes calculated
with 2−ΔCt formula which were correlated to the lowest normalized
expression measured by the applied qPCR method. For quantiﬁcation of
relative expression level of genes of interest, the normalized expression
data were analyzed using the comparative ΔΔCt method (Livak and
Schmittgen, 2001; Tóth et al., 2014).
2.11. Primary cell cultures and BBB model for permeability studies
Isolation of RBEC cells, glia and pericytes, and the construction of
the in vitro BBB model were performed according to the method de-
scribed in our previous studies (Nakagawa et al., 2009; Walter et al.,
2015). After isolation cells were seeded on culture dishes (Corning,
Costar, New York, NY, USA) coated with 100 μg/mL collagen type IV
and 100 μg/mL ﬁbronectin in sterile distilled water. RBEC cells were
cultured in DMEM/HAM's F-12 (Gibco, Life Technologies, Carlsbad, CA,
USA), 15% plasma-derived bovine serum (PDS, First Link, Wolver-
hampton, UK), 100 μg/mL heparin, medium supplement with 5 μg/mL
insulin, 5 μg/mL transferrin, 5 ng/mL sodium selenite (ITS, Pan-Biotech
Gmbh., Germany), 1 ng/mL basic ﬁbroblast growth factor (bFGF,
Roche, Basel, Switzerland) and 50 μg/mL gentamycin. During the ﬁrst
three days of culture the medium of RBEC cells contained 3 μg/mL
puromycin to eliminate P-glycoprotein negative, contaminating cell
types (Perrière et al., 2005).
For the permeability studies a triple co-culture BBB model was used
(Nakagawa et al., 2009). For this model, in addition to brain en-
dothelial cells, primary rat brain pericytes were isolated using the same
method as for brain endothelial cells, except that pericytes were plated
onto uncoated culture dishes and did not receive puromycin. Primary
cultures of rat glial cells were prepared from one-day-old Wistar rats
and passaged (8.5× 104 cells/cm2) to 12 well plates (Corning, Costar,
New York, NY, USA) coated with collagen type IV (100 μg/ml in sterile
distilled water). Rat glial cells were cultured for two weeks before using
them for the co-culture model (Veszelka et al., 2007). Pericytes and
glial cells were cultured in DMEM/HAM's F-12 supplemented with 10%
fetal bovine serum (FBS, Pan-Biotech GmbH) and 50 μg/mL genta-
mycin. To prepare the co-culture model, pericytes at P2 were passaged
(1.5×104 cells/cm2) to the collagen coated bottom side of tissue cul-
ture inserts (Transwell, polycarbonate membrane, 3 μm pore size,
Corning Costar) and brain endothelial cells were seeded
(7.5× 104 cells/cm2) to the upper side of the Matrigel (growth factors
reduced, Corning Costar, USA) coated membranes. Then the inserts
containing brain endothelial cells and pericytes on the two sides of the
membrane were placed to 12 well plates in which glial cells were grown
at the bottom (Fig. 1A). Both the upper and lower ﬂuid compartments
of this system received endothelial culture medium supplemented with
550 nM hydrocortisone and the three types of cells were cultured to-
gether for four days before permeability experiments (Nakagawa et al.,
2009; Walter et al., 2015).
2.12. Cell viability assay
Kinetics of RBEC cell reaction to niosome treatment were monitored
by impedance measurement (RTCA-SP instrument; ACEA Biosciences,
San Diego, CA). Impedance measurement is label-free, real time, non-
invasive, and correlates linearly with adherence and growth of cells.
After background measurements, cells were seeded at a density of
6× 103 cells/well in collagen coated 96-well plates with integrated
gold electrodes (E-plate 96, ACEA Biosciences). Cells were cultured for
5–7 days in CO2 incubator at 37 °C and monitored for 4 h. Triton X-100
detergent (10mg/mL) was used as a reference compound inducing cell
toxicity. Cell index was deﬁned as RneRb at each time point of mea-
surement, where Rn is the cell-electrode impedance of the well when it
contains cells and Rb is the background impedance of the well with the
medium alone. Cell index values reﬂect cell number and viability (Kiss
et al., 2013; Bocsik et al., 2016).
Fig. 1. (A) Schematic drawing of the BBB co-culture model. (B) Expression of
genes encoding solute carriers for glucose and alanine in isolated rat brain
microvessels and in primary rat brain endothelial cells in co-culture with rat
pericytes and astrocytes.
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2.13. Measurement of the uptake of niosomes in RBEC cells
The RBEC cells were cultured in 24 well plates (Corning Costar,
USA) at the density of 3×104 cells/well. The conﬂuent monlayers
were incubated with 10mg/mL niosome solutions (N, N-GP, N-A, N-
GSH, N-A-GP, N-GP-GSH, N-A-GSH) in culture medium for 4 h. The
uptake of single or dual-targeted niosomes in RBEC cells was tested at
4 °C and 37 °C. To elucidate the uptake mechanisms of targeted nio-
somes cells were co-treated with metabolic inhibitor sodium azide
(1mg/ml) or pretreated with endocytosis inhibitors, ﬁlipin (15min,
6 μM) and cytochalasin D (1 h, 20 μM) in culture medium. To study the
role of the surface charge in cellular uptake of NPs we digested the
surface glycocalyx of RBECs with neuraminidase (1 U/ml, 1-hour pre-
treatment), or treated the cells with 54 μM cationic lipid 1-(4-tri-
methylammoniumphenyl)-6-phenyl-1,3,5-hexatriene (TMA-DPH;
Molecular Probes, Life Technologies) for 30min before the uptake.
After incubation with niosomes RBECs were washed three times with
ice cold PBS supplemented with 1% BSA and once with acid stripping
buﬀer (glycine 50mM, NaCl 100mM, pH 3) to remove cell surface as-
sociated niosomes. Finally cells were lysed in PBS with Triton X-100
detergent (10mg/mL) and the ﬂuorescent signal was detected with a
spectroﬂuorometer (Horiba Jobin Yvon Fluorolog 3, Edison New
Jersey, USA) at 584 nm excitation and 663 nm emission wavelengths.
2.14. Visualization of the uptake of niosomes in RBEC cells
To visualize the cellular uptake of the ﬂuorescent particles RBECs
were grown on glass bottom Petri dishes coated with Matrigel and
treated with 10mg/mL niosomes for 4 h. The stain cell nuclei H33342
dye (1 μg/mL; 10min) was used. After incubation living cells were
washed three times with Ringer-Hepes buﬀer (118mM NaCl, 4.8mM
KCl, 2.5mM CaCl2, 1.2 mM MgSO4, 5.5mM D-glucose, 20mM Hepes,
pH 7.4) supplemented with 1% PDS and examined with a confocal laser
scanning microscope (Olympus Fluoview FV1000, Olympus Life
Science Europa GmbH, Hamburg, Germany).
The cellular uptake of targeted NPs was also examined by trans-
mission electron microscopy. RBECs were grown on culture inserts and
treated untargeted (N) or dual-targeted (N-A-GSH) niosomes (10mg/
ml) with lanthanum cargo for 4 h at 37 °C. Control cells were treated
0.2 μg/mL lanthanum, the same concentration entrapped in the nio-
somes. After incubation, RBECs were brieﬂy rinsed in 0.1 M phosphate
buﬀer (PB), then ﬁxed in 4% paraformaldehyde +2.5% glutaraldehyde
dissolved in 0.1M PB at 4 °C for 30min. After rinsing in 0.1M PB the
inserts were removed from the tissue culture plates and transferred into
50ml centrifuge tubes containing 0.1M PB and kept at 4 °C overnight.
Cells on the membranes were postﬁxed in 1% aqueous OsO4 for 1 h at
room temperature, washed in tri-distilled water for 10min and pro-
cessed in a graded series of ethanol (50%, 70%, 90%, 96%, 100%,
100%) for 10min in each solution. Then, 4–5mm small pieces of the
membranes with cells were embedded in Durcupan. Semithin (0.5 μm)
sections were cut from the blocks on a Reichert OM-U2 ultramicrotome,
which were stained to localize the cell layers on the membranes. Next,
ultrathin section (60 nm) were cut on a Leica Ultracut S ultra-
microtome, mounted either on formvar coated single slot or uncoated
300mesh copper grids, and stained with 2% uranyl acetate for 15min.
Sections were examined in a JEOL JEM 1400 Plus electron microscope
operated at 100 kV accelerating voltage. Digital images were taken with
a Matataki 8 MPix CCD camera at 16-bit gray scale color depth and
saved in uncompressed TIFF format.
2.15. Permeabilty of niosomes across the BBB co-culture model
The tightness of the BBB co-culture model was veriﬁed by mea-
surement of transendothelial electric resistance (TEER) by EVOM vol-
tohmmeter (World Precision Instruments, Sarasota, 45 FL, USA) com-
bined with STX-2 electrodes. When high TEER values
(539 ± 71Ω×cm2) were obtained, the model was used for experi-
ments. Cells were treated in the upper, donor compartment (0.5 mL)
with single or dual-targeted niosomes (10mg/mL) diluted in phenol red
free DMEM F12 supplemented with 1% PDS and 1% ITS for 4 h. After
incubation samples were collected from the lower, acceptor compart-
ments (1.5 mL) and measured with spectroﬂuorometer (Horiba Jobin
Yvon Fluorolog 3) at 584 nm excitation and 663 nm emission wave-
lengths. The apparent permeability coeﬃcients (Papp) were calculated
as described previously (Bocsik et al., 2016) by the following equation:
=
×
× ×
P Δ C V
A C Δt
(cm/s) [ ]
[ ]
A A
D
app
Brieﬂy, Papp (cm/s) was calculated from the concentration diﬀer-
ence of the NPs in the acceptor compartment (Δ[C]A) after 4 h. [C]D is
the concentration in the donor compartments at 0 h, VA is the volume of
the acceptor compartment (1.5 mL), and A is the surface area available
for permeability (1.1 cm2).
2.16. Measurement of plasma membrane ﬂuidity
RBECs grown in culture dishes were treated with N and N-A-GSH
(10mg/ml) diluted in culture medium for 4 h at 37 °C in a CO2 in-
cubator. The cells were washed twice with PBS, collected by trypsini-
zation, and resuspended in Ringer-Hepes buﬀer. The density of cells
was set by absorbance measurement to OD360= 0.1 (Hewlett Packard
8452A Diode Array Spectrophotometer). Cells were labeled with 0.2 μM
TMA-DPH for 5min. Fluorescence anisotropy was measured on a T-
format ﬂuorescence spectrometer (Quanta Master QM-1, Photon
Technology International, Princeton, NJ, USA). Excitation and emission
wavelengths were 360 and 430 nm, respectively (5 nm and 6 nm slits).
Cells were kept at 37 °C under stirring conditions. Anisotropy data were
acquired in every second for 5min, then benzyl alcohol (50mM; Merck,
Darmstadt, Germany), a strong membrane ﬂuidizer, was added and
data were acquired for another 5min. The average of 50 anisotropy
measurements in the last 1 min of each treatments was calculated and
compared (Kiss et al., 2014; Lénárt et al., 2015).
2.17. In vivo imaging of targeted niosomes
Ten-week old male CD1-Foxn1nu nude mice (Winkelmann,
Borchen, Germany) were used for in vivo imaging. Animals were kept
under conventional controlled conditions (22 °C, 55% humidity, day-
night rhythm) and had free access to a standard diet (ssniﬀ
Spezialdiäten GmbH, Soest, Germany) and tap water. A time domain in
vivo small animal ﬂuorescence imager Optix™ (ART, Montreal, Canada;
Keren et al., 2008; Kumar et al., 2008) was used to monitor the brain
penetration of the EBA cargo of niosomes in real-time and over several
time points in the same animal. Animals were placed in prone position
on the table of the imager. Anesthesia was maintained during the
ﬂuorescence detection by oﬀering an oxygen-isoﬂurane gas mix via a
small mask. EBA encapsulated in diﬀerent niosomes (N, N-A, N-GP, N-
A-GP) were injected intravenously (100 μL, tail vein). Fluorescence
measurement to visualize the EBA was performed repeatedly after
niosome injection at deﬁned time points up to 24 h (0, 10 and 30min,
3, 6 and 24 h). The animals were returned to their cage and provided
access to food and water between the longer measurement points.
Head-detector distance was equal in all measurements. The red ﬂuor-
escent signal of EBA was detected over the whole body of living an-
esthetized mice in 0.5mm steps. For ﬂuorescence detection, a time-
correlated single-photon counting system (TCSPC-130) was used. In-
tensity units were normalized for the same excitation power and ex-
citation time per raster point (integration time).
2.18. Statistical analysis
Data are presented as means ± SEM or SD. Values were compared
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using one-way or two-way analyses of variances following Dunnett or
Bonferroni multiple comparison posttests (GraphPadPrism 5.0;
GraphPad Software, USA). Changes were considered statistically sig-
niﬁcant at P < 0.05. All experiments were repeated at least two times
and the number of parallel samples was 4–10.
3. Results
3.1. Expression of selected Slc genes coding nutrient transporters
We veriﬁed the expression of genes for Slc transporters carrying
glucose and alanine in the BBB co-culture model and in freshly isolated
rat brain microvessels (Fig. 1B). Among the carriers of glucose the ex-
pression level of the gene Glut1, coding the predominant glucose
transporter at the BBB, was the highest, followed by Glut5 and Glut3 in
brain microvessels. In RBECs the relative transcript levels for Glut1 and
Glut3 were also high, while that of Glut5 was very low. All the tested
neutral amino acid transporter genes were detectable in both brain
microvessels and RBECs. The mRNA of Snat2 was expressed at the
highest level in both models. From the tested eight genes only in two
cases, for Glut5 and Snat5, were transcript levels much lower in RBECs
than in brain microvessels (Fig.1B).
3.2. Characterization of niosomes
Table 1 summarizes the main physicochemical properties of the
untargeted (N), single ligand targeted (N-GP, N-A, N-GSH), and dual-
ligand targeted (N-A-GSH, N-A-GP, N-GP-GSH) niosomes (for schematic
drawing see Fig. 2). The average diameter of the niosomes varied be-
tween 92 and 107 nm. All groups had low polydispersity index, in-
dicating a relatively narrow size distribution. The zeta potentials of
niosomes were between −3 and −4mV, except those decorated with
GSH ligand (N-GSH, N-A-GSH, N-GP-GSH), which had a more negative
surface charge, around −7mV. The encapsulation eﬃciency of the
cargo EBA was in the range of 4.6–10.4%. The amount of the en-
capsulated large hydrophilic biomolecule EBA was between 0.5 and
1.1 mg/100mg nanoparticle total weight (Table 1). The morphology of
the NPs was spherical as observed by transmission electron microscopy
(Fig. 3A) and atomic force microscopy (Fig. 3B). No aggregation was
visible.
The stability of untargeted niosome loaded with EBA was followed
for six months. The size of niosomes changed from 92.8 ± 1.8 nm to
119.5 ± 1.9 nm during this period. At 6months the polydispersity
index was 0.30 ± 0.003 indicating monodispersity, and the zeta po-
tential (−4.03 ± 0.49mV vs. −3.67 ± 0.09mV) and the encapsula-
tion eﬃciency (11.5% vs. 9.21%) have changed minimally. Based on
these data the niosome preparation can be considered as stable re-
garding size, encapsulated cargo and aggregation for at least 6 months.
3.3. Eﬀect of niosomes on cell viability of RBECs
Incubation of RBECs with non-targeted or targeted niosomes in the
0.3–10mg/mL concentration range for 4 h did not decrease the
impedance of cell layers reﬂecting good cell viability (Fig. 4). For fur-
ther experiments we selected the 10mg/mL concentration, which can
be considered as a safe concentration for all niosome groups.
3.4. Uptake of the cargo of single and dual-targeted niosomes in RBEC
The uptake of the large hydrophilic free EBA was very low in brain
endothelial cells, only 1.5% of the EBA uptake in cells treated with non-
targeted niosome containing the cargo (N) (Fig. 5). As compared to non-
targeted niosomes, the uptake of EBA in RBECs treated with nanove-
sicles decorated with alanine, glucopyranose or glutathione was higher
(N-A: 131%, N-GP: 130%, N-GSH: 191%). The presence of dual-ligands
statistically signiﬁcantly increased the cellular concentration of EBA in
brain endothelial cells in the case of N-A-GP (293%) and N-A-GSH
groups (249%), but not in the N-GP-GSH group.
Table 1
Characterization of the non-targeted and targeted niosomes.
Niosomes Size
(nm)
Polydispersity index Zeta potential (mV) Encapsulation eﬃciency (%) Encapsulated BSA (mg/100mg NP)
N 106 ± 10 0.18 ± 0.04 −3.41 ± 0.50 8.47 ± 3.24 0.85 ± 0.33
N-A 92 ± 40 0.18 ± 0.01 −4.36 ± 0.60 7.54 ± 3.57 0.75 ± 0.36
N-GP 98 ± 14 0.20 ± 0.04 −4.19 ± 0.29 4.90 ± 0.52 0.49 ± 0.05
N-GSH 107 ± 11 0.17 ± 0.02 −7.39 ± 0.77 10.43 ± 6.17 1.04 ± 0.62
N-A-GSH 103 ± 50 0.18 ± 0.01 −7.14 ± 1.15 6.14 ± 2.60 0.61 ± 0.26
N-A-GP 94 ± 10 0.17 ± 0.01 −3.83 ± 1.03 10.87 ± 0.53 1.09 ± 0.05
N-GP-GSH 101 ± 80 0.17 ± 0.01 −6.40 ± 1.27 4.66 ± 2.53 0.47 ± 0.25
Fig. 2. Schematic drawing of non-targeted (N), single ligand targeted (N-A:
alanine-, N-GP: glucopyranose-, N-GSH: glutathione-targeted) and dual-tar-
geted niosomes (N-A-GP: glucose-alanine-, N-A-GSH: alanine-glutathione-, N-
GP-GSH: glucose-glutathione-targeted).
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3.5. Penetration of the cargo by targeted niosomes across a BBB co-culture
model
The permeability of the BBB model for EBA was also very low
(0.13×10−6 cm/s) reﬂecting a tight barrier (Fig. 6). This Papp value
for EBA, a transendothelial marker molecule, is in accordance with our
previous results (Walter et al., 2015). The encapsulation of EBA in non-
targeted niosomes (N) increased the permeability of the cargo through
brain endothelial cells (0.28×10−6 cm/s). Labeling the particles with
single ligands resulted in further increase in the penetration of EBA
across the BBB model (N-A: 1.18× 10−6 cm/s; N-GP: 1.01×10−6 cm/
s; N-GSH: 1.29×10−6 cm/s). The amount of EBA cargo that crossed
brain endothelial cells was increased 17-fold in case of the N-A-GSH
group (2.26× 10−6 cm/s) and 14-fold in the N-A-GP group
(1.83×10−6 cm/s) as compared to the EBA group (Fig. 6). The com-
bination of GP-GSH ligands was not eﬃcient to elevate EBA penetration
across the BBB model. Based on the results, the N-A, N-GSH and N-A-
GSH groups were selected for further in vitro experiments.
3.6. Cellular uptake: Visualization
Since EBA, our model cargo gives a red ﬂuorescent signal (Uyama
et al., 1988), the uptake of free EBA and EBA encapsulated in nano-
vesicles (N, N-A-GSH) was visualized in RBECs by confocal microscopy
(Fig. 7A). Red ﬂuorescence was detected in cells treated with dual-
targeted N-A-GSH niosomes indicating uptake of the cargo. Less ﬂuor-
escent signal was seen in the non-targeted vesicle (N) group, while the
cellular entry of free dye (EBA) was barely detectable.
For transmission electron microscopy the cells were treated with
free lanthanum (LA), lanthanum entrapped non-targeted niosomes (N)
and vesicles labeled with dual-ligands containing lanthanum (N-A-GSH)
(Fig. 7B). The particles were non toxic (data not shown) and their
physicochemical properties (N: 110 nm, −2.25mV; N-A-GSH: 115 nm,
−5.08mV) were similar to the niosomes ﬁlled with EBA. The con-
centration of lanthanum was equal in each groups. More dark pre-
cipitates and structures can be seen in cells treated with N-A-GSH
compared to the untargeted nanoparticle (N) and lanthanum groups.
3.7. Cellular uptake: Temperature dependence and metabolic inhibition
To test the temperature dependence of the cellular uptake of na-
novesicle encapsulated EBA, cells were treated with selected niosomes
(N, N-A, N-GSH, N-A-GSH) at both 4 °C and 37 °C (Fig. 8). At 37 °C the
EBA uptake was signiﬁcantly higher in all targeted nanovesicle groups
(N-A: 119%, N-GSH: 150%, N-A-GSH: 308%) compared to the non-
targeted group (N: 100%). Decreased EBA uptake was seen in RBECs at
4 °C (N-A: 36%, N-GSH: 55%, N-A-GSH: 17%) as compared to the non-
targeted group at 37 °C. Treatment of the cells with metabolic inhibitor
sodium azide resulted in lower uptake of the cargo (N-A: 88%, N-GSH:
113%, N-A-GSH: 81%) compared to data measured at 37 °C in the same
treatment groups (Fig. 8).
3.8. Cellular uptake: Inhibition of endocytosis
Two inhibitors of endocytosis (Ivanov, 2008) were used to further
elucidate the mechanism of cellular uptake of EBA after treating the
cells with dual-targeted N-A-GSH particles (Fig. 9A). Filipin, which
inhibits lipid raft/caveolae-mediated endocytosis, slightly, but statisti-
cally signiﬁcantly decreased the uptake of cargo in RBECs (94% of the
control group). Cytochalasin-D, a common inhibitor of endocytosis by
blocking F-actin depolymerization, also induced a partial, but sig-
niﬁcant inhibition of EBA uptake (80% as compared to the control
group).
3.9. Cellular uptake: Modiﬁcation of cell surface charge
We modiﬁed the surface charge of cultured brain endothelial cells
by digestion of the surface glycocalyx with neuraminidase enzime
(Singh et al., 2007) and treatment with a cationic lipid, TMA-DPH
(Ribeiro et al., 2012). Surface charge alterations in RBECs did not aﬀect
the cellular uptake of EBA after treatment with non-targeted NPs as
compared to the control, untreated group (Fig. 9B). In contrast, both
modiﬁcations increased signiﬁcantly the uptake of EBA in brain en-
dothelial cells after incubation with N-A-GSH niosomes (Fig. 9B). The
uptake of EBA was increased by 16%, after treatment of RBECs with
neuraminidase and by 19% after incubation with TMA-DPH, as com-
pared to untreated cells in the N-A-GSH nanoparticle group.
Fig. 3. (A) Transmission electron microscopy image of niosomes, bar: 500 nm.
(B) Atomic force microscopy image of niosomes.
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3.10. Interaction of nanovesicles with RBECs: Plasma membrane ﬂuidity
The membrane ﬂuidity of brain endothelial cells, determined by
ﬂuorescence anisotropy (Kiss et al., 2014), was signiﬁcantly decreased
after 4 h treatment with N and N-A-GSH nanovesicles (Fig. 10) in-
dicating increased cell membrane ﬂuidity and a fusion process. The
membrane ﬂuidizer benzyl alcohol (30mM) quickly and greatly re-
duced the TMA-DPH ﬂuorescence anisotropy after 3min compared to
the control and niosome treated groups indicating maximal plasma
membrane ﬂuidity.
3.11. Imaging of EBA in mice after intravenous injection of targeted
niosomes
Brain penetration of the red ﬂuorescent EBA was measured by
imaging in nude mice. Free EBA and EBA encapsulated in targeted and
non-targeted niosomes were injected intravenously. There was no
Fig. 4. The eﬀect of non-targeted (N), ala-
nine-targeted (N-A), glucopyranose-tar-
geted (N-GP) and glutathione-targeted (N-
GSH) niosomes on the viability of brain
endothelial cells after 4-hour incubation.
Values presented are means ± SEM.
Statistical analysis: ANOVA followed by
Dunnett's posttest, *P < 0.05, **P < 0.01,
***P < 0.001, compared to control group,
n=8. C: medium treated control group.
Fig. 5. The uptake of non-targeted (N), single- (N-A, N-GP, N-GSH) and dual-
targeted (N-A-GP, N-A-GSH, N-GP-GSH) niosomes in brain endothelial cells
after 4-hour incubation. Values presented are means ± SEM. Statistical ana-
lysis: ANOVA followed by Dunnett's posttest, where ***P < 0.001, compared
to non-targeted N group; n=10.
Fig. 6. Permeability of albumin cargo across the culture BBB model after
treatment with diﬀerent niosomes (10mg/mL, 4 h). Values presented are
means ± SEM. Statistical analysis: ANOVA, Dunnett's posttest. **P < 0.01,
compared to non-targeted N group; n= 10.
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signiﬁcant accumulation of ﬂuorescent signal in the brain area in the
case of free EBA (Fig. 11). Encapsulation of EBA in non-targeted nio-
somes resulted in enhanced brain ﬂuorescent intensity. The ﬂuorescent
signal in the brain area was further increased in the single ligand tar-
geted N-A and N-GP groups. Fluorescent signal from EBA cargo in the
dual-ligand targeted N-A-GP group was the highest as compared to all
groups at all time points (Fig. 11). The diﬀerences between targeted,
dual-ligand targeted and non-targeted niosomes were still visible at
24 h.
4. Discussion
4.1. Functionalization of NPs for BBB targeting by SLC ligands
Nanocarriers are intensively investigated as novel therapeutic tools
to prevent or to treat CNS disorders (Masserini, 2013; Loureiro et al.,
2015; Saraiva et al., 2016). The key problem for the eﬀective targeting
of NPs to brain is the proper functionalization of these carriers to cross
the BBB (Wohlfart et al., 2012; Masserini, 2013; Kreuter, 2014). NPs
accumulate in several organs, including liver, spleen, and kidney, and
only speciﬁc BBB targeting can increase the ratio of nanocarriers pe-
netrating the CNS (Saraiva et al., 2016). To ensure this relative brain
speciﬁcity it is important to functionalize the NPs with targeting mo-
lecules which are substrates of physiological transporters of the BBB
and able to trigger active and speciﬁc transport mechanisms to cross the
BBB.
As compared to BBB receptors, SCLs are underresearched as mole-
cular targets of CNS drug delivery systems (Rask-Andersen et al., 2013).
The glucose consumption of the brain is the highest among the organs,
and hexose transporters, especially GLUT-1 (SLC2A1), are highly ex-
pressed at the BBB (Campos-Bedolla et al., 2014). We conﬁrmed that
several glucose transporters were expressed in isolated rat brain mi-
crovessels and in brain endothelial cells of the BBB co-culture model
with the Glut1 gene showing the highest mRNA expression. N-dodecyl-
β-D-glucopyranose was selected as a non-degraded glucose analog to
decorate the niosomes. Using culture models of the BBB we found about
30% increase in the uptake and three-fold elevation in the permeability
of the EBA cargo with N-GP, as compared to non-targeted niosomes, but
Fig. 7. (A) Confocal microscopy images of cultured brain endothelial cells incubated with unencapsulated cargo (EBA, showing red ﬂuorescence), non-targeted (N) or
alanine-glutathione-targeted (N-A-GSH) niosomes for 4 h at 37 °C. Cell nuclei were stained with bis-benzimide (blue). Bar: 20 μm. (B) Transmission electron mi-
croscopy images of the uptake of free lanthanum (LA) and lanthanum (black arrows) encapsulated in non-targeted (N) or alanine-glutathione-targeted (N-A-GSH)
niosomes in brain endothelial cells after 4 h incubation. Bar: 0.5 and 1 μm. TJ: tight junction. (For interpretation of the references to color in this ﬁgure legend, the
reader is referred to the web version of this article.)
Fig. 8. The eﬀect of temperature and metabolic inhibitor sodium azide (0.1%)
on the uptake of EBA cargo in brain endothelial cells after 4 h incubation with
non-targeted (N), alanine-targeted (N-A), glutathione-targeted (N-GSH) and
alanine-glutathione-targeted (N-A-GSH) niosomes. Values presented are
means ± SEM. Statistical analysis: two-way ANOVA, Bonferroni posttest.
*P < 0.5; **P < 0.01; ***P < 0.001, compared to ﬁrst column of each
groups, ###P < 0.001, compared to N treated group; n=4–6.
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these changes were statistically not signiﬁcant. In mice the brain
ﬂuorescence of EBA signiﬁcantly increased at 10min and several fold
elevation was observed until 24 h after tail vein injection of N-GP. Our
in vivo results are in agreement with the ﬁndings of Dufes et al., who
described that niosomes targeted with N-palmitoylglucosamine ligand
enhanced the brain entry of the cargo vasoctive intestinal peptide in
mice (Dufes et al., 2004). Small gold NPs covalently coated with β2-
mercaptoethoxy-glucose entered and crossed cultured human brain
endothelial cells better than non-brain endothelial cells (Gromnicova
et al., 2013). Nanoparticles, including liposomes, micelles and solid
polymeric NPs derivatized with diﬀerent glucose analogs improve the
delivery of encapsulated drugs or ﬂuorescent dyes to the brain by tar-
geting GLUTs as reviewed by Patching (2017) indicating the potential
applicability of these SLCs.
The small neutral amino acid alanine, which is transported by
several SLCs at the BBB (Campos-Bedolla et al., 2014), was selected as
the other targeting ligand of the tested niosomes. The mRNAs of both
the sodium coupled and neutral amino acid carriers were highly re-
presented in brain microvessels and the BBB culture model. To our best
knowledge, this is the ﬁrst report indicating that NPs decorated with
alanine as a targeting ligand elevated the uptake of the cargo in
cultured brain endothelial cells (Fig. 8) and its brain entry in mice
(Fig. 11).
As a reference targeting ligand niosomes were also functionalized
with glutathione. Labeling of niosomes with GSH-PEG signiﬁcantly
increased the uptake of EBA in primary RBECs (Fig. 8) and elevated
four-fold the EBA permeability across the BBB culture model as com-
pared to untargeted NPs (Fig. 6). These ﬁndings are supported by data
showing that GSH targeting of liposomes elevated the uptake of car-
boxiﬂuorescein in RBE4 rat brain endothelial cell line (Rip et al., 2014)
and that of doxorubicin in hCMEC/D3 human brain endothelial cell line
(Gaillard et al., 2014). GSH labeling also elevated the permeability of
solid NPs across BBB culture models (Grover et al., 2014; Veszelka
et al., 2017). The GSH-PEGylated liposomal drug delivery system was
eﬀective in rodent models for brain delivery of diﬀerent drug cargos,
like doxorubicin (Gaillard et al., 2014) or ribavirin (Maussang et al.,
2016), indicating the in vivo applicability of GSH and the predictive
value of in vitro BBB models.
4.2. Dual targeting of BBB transporters
In concordance with our hypothesis, dual labeling of niosomes with
ligands of BBB transporters (N-A-GP and N-A-GSH) elevated the cargo
uptake in RBECs and penetration across the BBB model as compared to
both single ligand targeted or untargeted NPs. The eﬀect of dual la-
beling of NPs with SLC substrates (N-A-GP) on brain uptake of cargo
was the highest in the mouse study (Fig. 11). The cargo selected for our
study, the large biomolecule albumin, has a negligible transport across
the BBB in physiological conditions (Abbott et al., 2010). This is also
reﬂected in the very low Papp value (0.1× 10−6 cm/s) of the free EBA
across the BBB model (Fig. 6), in accordance with our previous data
(Deli et al., 2005; Walter et al., 2015; Veszelka et al., 2018). Free EBA
cargo penetration to brain was also limited in mice (Fig. 11), as we
demonstrated it in our previous study (Veszelka et al., 2003). It should
be noted, that compared to small molecule permeability, the Papp value
of EBA increased by dual targeted nanovesicles is still low (Fig. 11). We
should consider however, that this limited EBA transport represent 10-
and 20-fold increases in the Papp value or in the brain ﬂuorescence
intensity, respectively, of this low penetrant cargo.
As a possible mechanism, the combination of two diﬀerent SLC
transporter ligands on the niosomal surface may produce stronger ve-
sicular docking to brain endothelial cells facilitating NP fusion and/or
endocytosis. There are two studies which may support this dual BBB
targeting hypothesis, although with diﬀerent systems. Liposomes
Fig. 9. (A) Inhibition of the uptake of EBA cargo with ﬁlipin (6 μM) or cyto-
chalasin D (20 μM) in rat brain endothelial cells after 4 hours incubation with
alanine-glutathione duale-targeted niosomes (N-A-GSH). Values presented are
means ± SEM. Statistical analysis: ANOVA followed by Dunnett's posttest
where *P < 0.5; ***P < 0.001, compared to the control group; n=6. (B) The
eﬀect of neuraminidase (1 U/ml) and TMA-DPH (30mM) on the uptake of EBA
cargo in brain endothelial cells incubated with non-targeted (N) and alanine-
glutathione dual-targeted niosomes (N-A-GSH). Statistical analysis: two-way
ANOVA, Bonferroni posttest. **P < 0.01 compared to ﬁrst column of each
groups; ###P < 0.001, compared to N treated groups; n=6.
Fig. 10. The eﬀect of non-targeted (N) and alanine-glutathione dual-targeted
niosomes (N-A-GSH) and benzyl alcohol (30mM) on plasma membrane ﬂuidity
measured by ﬂuorescence anisotropy on living brain endothelial cell suspen-
sions. Values presented are means ± SEM. Statistical analysis: two-way
ANOVA, Bonferroni posttest. ***P < 0.001, all groups were compared to non-
treated control (C); ###P < 0.001, compared to ﬁrst column of each groups,
n=3.
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(100 nm) were dually decorated with ligands of the transferrin and LRP
receptors expressed at the BBB (Markoutsa et al., 2014). Dual-targeting
for BBB receptors increased BBB penetration of NPs both in cultured
brain endothelial cells and in mice, indicating that targeting more than
one receptors at the BBB can be more eﬀective, similarly to targeting
multiple BBB transporters. In another study 2 nm carbon dots prepared
by pyrolysis from D-glucose and L-aspartic acid penetrated glioma tissue
better than normal brain in mice, but not carbon dots prepared from D-
glucose, L-aspartic acid, or D-glucose and L-glutamic acid (Zheng et al.,
2015). In this study, however, no experiments were done to reveal the
uptake mechanism(s) and whether this was an active, energy dependent
process.
Dual-targeted drug delivery systems are also described for other
glioma preclinical models, but in these cases not multiple BBB trans-
porters are involved. For example, the ligand of hexose transporters, 2-
deoxy-D-glucose, was used as a NP ligand targeting both the BBB and
the glioma cells (Jiang et al., 2014). In other systems even if two dif-
ferent ligands are used, only one is speciﬁc for the BBB, the other ligand
serves for diﬀerent purposes, like cell penetration. The combination of
T7 peptide targeting TfR at the BBB and the cell-penetrating peptide
TAT enhanced the eﬃciency of glioma targeting of liposomes (Zong
et al., 2014).
4.3. Mechanism of targeted NP uptake
Modiﬁed physiological conditions, such as low temperature or the
inhibition of ATP hydrolysis can help to identify the cellular uptake
mechanisms of NPs (Fiorentino et al., 2015). In our study the uptake of
cargo was decreased in the targeted NP groups by both low temperature
and the metabolic inhibitor sodium azide, which is consistent with the
hypothesis that the cellular uptake of targeted niosomes was an energy-
dependent active process. In agreement with our experiments the up-
take of GSH labeled liposomes in brain endothelial cells was also in-
hibited by low temperature (Maussang et al., 2016).
We also supposed that endocytotic processes might participate in
the uptake of targeted niosomes, therefore we used inhibitors of en-
docytosis, cytochalasin D and ﬁlipin. Cytochalasin D is a drug blocking
F-actin depolymerization, membrane ruﬄing and thereby inhibiting
macropinocytosis and phagocytosis. Since actin cytoskeleton regulates
several endocytotic pathways cytochalasin D is a common inhibitor of
endocytosis (Ivanov, 2008). Cytochalasin D pretreatment inhibited the
uptake of GSH-PEG liposomes in hCMEC/D3 endothelial cell line
(Maussang et al., 2016) as well as the uptake of platelet-derived mi-
croparticles (Faille et al., 2012) indicating that the internalization of
extracellular NPs into endocytotic vesicles might be an important step
in the cellular uptake mecanisms. The antibiotic ﬁlipin interacts with
cholesterol in the biological membranes and inhibits selectively the
lipid raft and caveolae-mediated endocytosis (Ivanov, 2008). Pretreat-
ment of brain endothelial cells with cytochalasin D or ﬁlipin sig-
niﬁcantly decreased the uptake of the cargo in the case of dual-targeted
niosomes (N-A-GSH). These data indicate that endocytosis contributes
to the cellular uptake of targeted niosomes.
Several speciﬁc features of the BBB limit the penetration of drugs to
CNS. Intercellular junctions and drug eﬄux pumps are widely in-
vestigated, but the role of the negative surface charge of brain en-
dothelial cells in CNS drug delivery is rather unexplored. This highly
negative surface charge is composed of the negatively charged lipids in
the cellular plasma membrane and the glycocalyx at the luminal sur-
face. The glycocalyx is a 0.1–1 μm thin layer covering the entire surface
of endothelial cells and composed of proteoglycans and glycosami-
noglycans (Hervé et al., 2008). The surface charge of cells can be
measured by dynamic light scattering (zeta-sizer) and was found to be
the most negative in brain endothelial cells among vascular endothelial
cells (Ribeiro et al., 2012). This electrostatic barrier may inﬂuence the
transport of substances and also NPs across the BBB. While NP surface
charge was already investigated on BBB integrity and permeability
(Fenart et al., 1999; Lockman et al., 2004), the eﬀect of brain en-
dothelial surface charge modiﬁcation on the permeability of NPs was
not measured yet. We modiﬁed the highly negative surface charge with
neuraminidase and the TMA-DPH cationic lipid. The neuraminidase or
sialidase digests the negatively charged sialic acid residues on the lu-
minal surface of vascular endothelial cells and elevates the surface
charge of glycocalyx (Born and Palinski, 1985). In our experiments
neuraminidase treatment of brain endothelial cells signiﬁcantly in-
creased the uptake of the cargo of dual-targeted NPs compared with the
untargeted and non-treated groups. TMA-DPH elevates the charge of
the plasma membrane because it intercalates with the hydrophilic head
groups of membrane phospholipids (Ribeiro et al., 2012). TMA-DPH
also raised the cellular uptake of cargo in the dual-targeted NP group,
similarly to neuraminidase. Our new observations indicate that surface
charge at the BBB is important in the uptake mechanism of charged NPs
and can be modulated by modiﬁcation of plasma membrane lipid
composition or the glycocalyx.
Surfactants are well known enhancers of absorption and increase
drug permeability through the cell membranes or via the modulation of
intercellular junctions (Deli, 2009). Surfactants are incorporated into
the lipid bilayer of cell membranes, and depending on their con-
centration either change the physical properties and permeability of
plasma membranes or result in membrane solubilization leading to cell
toxicity (Ujhelyi et al., 2012). Polysorbate surfactants, especially
Fig. 11. Fluorescent intensity of EBA in the brain regions of mice after injection of free EBA or EBA encapsulated in non-targeted (N), single- (N-A, N-GP) or dual-
targeted (N-A-GP) niosomes measured by optical imaging. Values presented are means ± SD. Statistical analysis: two-way ANOVA, Bonferroni posttest. *P < 0.5;
**P < 0.01; ***P < 0.001, as compared to the EBA-treated group within each time point; a: as compared to the 10min, b: as compared to the 30min, c: as
compared to the 3 h, d: as compared to the 6 h time points within each group, n=3–4.
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Solulan C24 which is one of the main components of our niosomes
concentration-dependently increased the transepithelial permeability of
hidrophilic drug as a result of solubilization of membrane components
of Caco-2 cells (Dimitrijevic et al., 2000). We have previously demon-
strated that the non-ionic surfactant sugar esters increased the plasma
membrane ﬂuidity of epithelial cells which could contribute to the in-
creased transcellular passage of molecules (Kiss et al., 2014). In the
present experiments both the non-targeted and dual-targeted niosomes
decreased the ﬂuorescent anisotropy in brain endothelial cells, which
indicates increased cell membrane ﬂuidity, suggesting the fusion of the
nanovesicles with the plasma membrane.
4.4. Possible advantages and limitations of niosomes targeting BBB as a
delivery system
Niosomes in terms of stability and permeability for drug-size mo-
lecules are comparable to liposomes (Abdelkader et al., 2014; Bartelds
et al., 2018). In addition, the components of niosomes are cheap, not
sensitive for oxidation, and can be easily stored and handled. Similarly
to liposomes, they are suitable for the encapsulation of both water and
lipid soluble molecules (Abdelkader et al., 2014). Before our study, the
3.3 kDa hormone, vasoctive intestinal peptide, was the largest cargo
encapsulated in niosomes and targeted successfully to brain in mice
(Dufes et al., 2004). The molecular mass of our cargo, serum albumin is
20 times bigger, suggesting that niosomes are able to deliver large
biomolecules. Due to their non-ionic components and good biode-
gradability niosomes show low toxicity (Abdelkader et al., 2014). It
should be noted, that non-ionic surfactants may increase in a con-
centration dependent way the plasma membrane ﬂuidity of mammalian
cells, as we demonstrated in our previous study with sucrose esters (Kiss
et al., 2014), and in our present study with niosomes. This eﬀect may
help in the delivery of molecules, but can also contribute to cellular
toxicity. While liposomes are already used in pharmacotherapy, only
preclinical data, but no clinical studies were reported for niosomes. To
assess the eﬃcacy of BBB targeted niosomes as a delivery system,
comparative studies including other nanoparticles, like liposomes, and
other targeting ligands are needed.
4.5. Conclusion
Ligands targeting brain endothelial transporters elevated the per-
meability of the albumin cargo across the BBB in the culture model and
in mice, and dual-ligand decoration of niosomes was more eﬀective
than single ligand labeling. Our data indicate that dual labeling with
ligands of multiple SLC transporters can potentially be exploited for
BBB targeting of NPs.
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